Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetically engineered bacteria are sweet success against IBD

24.08.2009
For the first time, scientists have used a genetically engineered "friendly" bacterium to deliver a therapy.

The treatment is for bowel disorders such as inflammatory bowel disease, which affects one in 400 people in the UK and for which there is no cure. The bacterium Bacteroides ovatus activates a protein when exposed to a specific type of sugar, xylan. In research to be published in Gut, the therapy has been proven to work in animals with colitis, one of the major forms of inflammatory bowel disease.

The bacterium is able to deliver the protein, a human growth factor called KGF-2, directly to the damaged cells that line the gut, unlike other treatments which can cause unwanted side effects. Also unlike other treatments, it is envisaged that patients will be able to control the medication themselves by ingesting xylan, perhaps in the form of a drink.

"This is the first time that anyone has been able to control a therapeutic protein in a living system using something that can be eaten," said Professor Simon Carding of the Institute of Food Research and the University of East Anglia Medical School, lead author on the research. "The beneficial bugs could be activated when they are needed."

The treatment had a significant therapeutic effect. For example, it reduced rectal bleeding, accelerated the healing of the gut lining, and reduced inflammation. It was also able to prevent the onset of disease.

"The bacterium is being used to produce other protein molecules to treat various bowel disorders and we are now applying for funding to try out the bug in humans," said Dr. Zaed Hamady, an MRC Research Fellow at Leeds University.

Since genetic engineering techniques were developed in the 1970s, scientists have found ways to apply them to medicine. Insulin was the first medicine to be genetically engineered and the first genetically engineered vaccine was for hepatitis B. The technology is now opening up ways to deliver drugs to specific targets, as with this treatment to deliver a protein directly to injured areas of the gut.

"Initially I envisage this being an adjunct therapy to patients' existing medicine, but eventually it could be the sole therapy," said Professor Carding. "Once our bugs are in the colon they could be activated when needed so we aim to use our bugs to prevent disease or relapse in IBD."

The work was funded by a grant from the Medical Research Council and the Royal College of Surgeons, and by Techtran. The Institute of Food Research is an institute of Biotechnology and Biological Sciences Research Council.

Zoe Dunford | EurekAlert!
Further information:
http://www.bbsrc.ac.uk

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>